{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 3846,
  "pageSize": 60,
  "pageCount": 5333,
  "rows": [
    {
      "docId": "019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "docSlug": "d6b317a5031b61a1bc268fdc9db9f19f",
      "documentTitle": "Hugo Boss | Results Presentation Deck | 44 slides",
      "authorId": "hugo-boss",
      "authorName": "Hugo Boss",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "propose_solution",
      "function": "propose_solution",
      "notes": "The slide uses a four-column layout with upward-pointing arrows to signify growth/improvement.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0bf4-76bf-a8bd-32e390e8ddd9/40",
      "deckHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "deckAnchorHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 33,
          "beatId": "8edae348-4a8f-431e-97a6-32f352aaeaa5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The document concludes with a clear outlook for 2024 and a call to action, encouraging the audience to take note and consider the company's proposal",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "docSlug": "d6b317a5031b61a1bc268fdc9db9f19f",
      "documentTitle": "Hugo Boss | Results Presentation Deck | 44 slides",
      "authorId": "hugo-boss",
      "authorName": "Hugo Boss",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The slide uses a split-screen layout with key drivers on the left and a bar chart on the right.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0bf4-76bf-a8bd-32e390e8ddd9/41",
      "deckHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "deckAnchorHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 33,
          "beatId": "8edae348-4a8f-431e-97a6-32f352aaeaa5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The document concludes with a clear outlook for 2024 and a call to action, encouraging the audience to take note and consider the company's proposal",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "docSlug": "d6b317a5031b61a1bc268fdc9db9f19f",
      "documentTitle": "Hugo Boss | Results Presentation Deck | 44 slides",
      "authorId": "hugo-boss",
      "authorName": "Hugo Boss",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "thesis_headline",
      "function": "summarize",
      "notes": "This is a transition or summary slide, likely setting the stage for the operational and financial sections of the presentation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0bf4-76bf-a8bd-32e390e8ddd9/42",
      "deckHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "deckAnchorHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 33,
          "beatId": "8edae348-4a8f-431e-97a6-32f352aaeaa5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The document concludes with a clear outlook for 2024 and a call to action, encouraging the audience to take note and consider the company's proposal",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "docSlug": "d6b317a5031b61a1bc268fdc9db9f19f",
      "documentTitle": "Hugo Boss | Results Presentation Deck | 44 slides",
      "authorId": "hugo-boss",
      "authorName": "Hugo Boss",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "closing_ask",
      "function": "closing_ask",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0bf4-76bf-a8bd-32e390e8ddd9/43",
      "deckHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "deckAnchorHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 33,
          "beatId": "8edae348-4a8f-431e-97a6-32f352aaeaa5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The document concludes with a clear outlook for 2024 and a call to action, encouraging the audience to take note and consider the company's proposal",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "docSlug": "d6b317a5031b61a1bc268fdc9db9f19f",
      "documentTitle": "Hugo Boss | Results Presentation Deck | 44 slides",
      "authorId": "hugo-boss",
      "authorName": "Hugo Boss",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0bf4-76bf-a8bd-32e390e8ddd9/44",
      "deckHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9",
      "deckAnchorHref": "/decks/019de077-0bf4-76bf-a8bd-32e390e8ddd9#slide-44",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 33,
          "beatId": "8edae348-4a8f-431e-97a6-32f352aaeaa5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The document concludes with a clear outlook for 2024 and a call to action, encouraging the audience to take note and consider the company's proposal",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/6v2syC2Re7fcxeNHLt6-D3KJ5t9Is4V7m3jKnl4LUZc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YmM5ODQ5MjFkYTE2ZDBlMDdkZWZiNjZiYTBjZTBhMS9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/1",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/qId8vcfeWVMsnx9jo6I73kvvJW33LGdWYUV4rE6Vm5Y/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YmM5ODQ5MjFkYTE2ZDBlMDdkZWZiNjZiYTBjZTBhMS9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/7RVLy6Zpa6g8z5gOSVJNjx7SlqGHIcZ2lEZCF9JSLXE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YmM5ODQ5MjFkYTE2ZDBlMDdkZWZiNjZiYTBjZTBhMS9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/STa5py6nuotBzl0EMqZoNM8vQF6SCtp-uUBDb0TFrD0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YmM5ODQ5MjFkYTE2ZDBlMDdkZWZiNjZiYTBjZTBhMS9wMDAxLnBuZw"
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/2",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "The slide uses a three-column layout for strategic pillars followed by a bottom section highlighting clinical performance metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/3",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "team_bio",
      "function": "other",
      "notes": "The slide uses a grid-based layout to categorize team members into three distinct organizational tiers.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/4",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a Gantt-style chart to represent clinical trial stages.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/5",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "timeline",
      "function": "plan_implementation",
      "notes": "The slide uses a visual arrow graphic to imply forward momentum.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/6",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a structural diagram to map technical modifications to clinical outcomes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/7",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-7",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 7,
          "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a comparison framework to contrast standard industry benchmarks with the company's clinical data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/8",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-8",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 7,
          "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a process flow diagram to connect cellular pathology to clinical organ damage.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/9",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-9",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 9,
          "beatId": "49cd16bb-edc2-4938-8179-50372f2e2ebe",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "Slide 9: NXC-201 targets AL amyloidosis plasma cells that express BCMA on cell surface",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        },
        {
          "to": 12,
          "from": 7,
          "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/10",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-10",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 7,
          "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/11",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-11",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 7,
          "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/12",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-12",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 12,
          "from": 7,
          "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "Uses a bar chart to compare CRS duration in days across four competitors, with NXC-201 highlighted as significantly lower.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/13",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-13",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 14,
          "from": 13,
          "beatId": "6c774e15-c7dc-4c42-8c64-b7875ced2bf7",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "Slides 13-14: NXC-201's short CRS duration makes it uniquely suitable to treat ALA patients; NXC-201: \"Single-Day CRS\", Overcoming Neurotoxicity",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a bar chart to compare neurotoxicity percentages and a table to compare clinical metrics like CRS onset and duration.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/14",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-14",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 14,
          "from": 13,
          "beatId": "6c774e15-c7dc-4c42-8c64-b7875ced2bf7",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "Slides 13-14: NXC-201's short CRS duration makes it uniquely suitable to treat ALA patients; NXC-201: \"Single-Day CRS\", Overcoming Neurotoxicity",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide highlights NXC-201's 100% overall response rate and superior cardiac response compared to CAEL-101 and Birtamimab.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/15",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-15",
      "loopMatches": [
        {
          "to": 15,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
          "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
          "position": 0,
          "objective": "What are the consequences of not adopting NXC-201?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a swimmer plot showing patient response duration, with an annotation indicating the target population for future enrollment.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/16",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-16",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/17",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-17",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 17,
          "beatId": "554702d9-4f5c-4012-bea2-07d35084ca95",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Market Size",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "Slide 17: NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "N-GENIUS TECHNOLOGY PLATFORM; NEXICART-1 Clinical Trial Data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/18",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-18",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes comparative data points for transduction efficiency and experimental data for tonic signaling and exhaustion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/19",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-19",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/20",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-20",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/21",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-21",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a schematic to compare HSL and LSH configurations, showing superior performance for HSL in expansion and cytotoxicity metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/22",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-22",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes a footnote citing FDA approval precedents for single-arm studies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/23",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-23",
      "loopMatches": [
        {
          "to": 23,
          "from": 16,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
          "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
          "position": 1,
          "objective": "What are the potential benefits of NXC-201 in the market?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "appendix",
      "function": "appendix",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/24",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a comparative diagram to show structural differences between NXC-201 and Abecma.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/25",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows a summation of two patient groups (prevalence and incidence-derived relapsed/refractory) to reach a total eligible patient count.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/26",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "unfair_advantage",
      "function": "present_solution",
      "notes": "The slide uses a molecular biology diagram to illustrate structural differences in binding domains and intracellular signaling components.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/27",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a visual comparison of three treatment timelines to highlight the superior safety profile of NXC-201.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/28",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The table compares NXC-201 against Darzalex, CAEL-101, and Birtamimab across various clinical metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/29",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Uses a before-and-after framing to illustrate market expansion potential.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/30",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a structural layout to map platform capabilities to specific therapeutic products.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/31",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "roadmap",
      "function": "show_traction",
      "notes": "The slide uses a step-diagram to illustrate dose escalation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/32",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a process diagram illustrating the medical procedure and a list of key attributes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/33",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "why_now",
      "function": "argue_timing",
      "notes": "Includes a comparative table of clinical outcomes (ORR, CR/sCR) for NXC-201 vs competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/34",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-34",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 35,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table highlights low incidence of severe adverse events and management protocols for NXC-201.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/35",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-35",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 36,
      "slideType": "peer_benchmark",
      "function": "compare_peers",
      "notes": "The slide highlights safety data (CRS and ICANS) and toxicity management interventions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/36",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-36",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 37,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "NXC-201 is highlighted with an orange border to emphasize its specific regimen.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/37",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-37",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The table compares clinical trial inclusion criteria across four different therapies for relapsed/refractory multiple myeloma.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/38",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "Highlights NXC-201's competitive advantage regarding prior BCMA therapy exclusion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/39",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a numbered process flow layout.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/40",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses cross-trial comparison; disclaimer notes these are not head-to-head results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/41",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "other",
      "function": "present_solution",
      "notes": "Includes a scientific mechanism of action diagram at the bottom.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/42",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a segmented horizontal axis to compare two distinct market segments by revenue.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/43",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a hub-and-spoke style diagram to link the platform pillars to specific drug candidates.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/44",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-44",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Slide contains three distinct data charts and a summary of clinical trial plans.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/45",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-45",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 46,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes three distinct proof-of-concept data panels (penetration, biodistribution, apoptosis).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/46",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-46",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 47,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes waterfall chart and longitudinal line charts for patient cohorts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/47",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-47",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 48,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a bubble chart to show clinical trial outcomes and a table to detail efficacy/safety metrics across treatment lines.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/48",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-48",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 49,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy and safety in heavily pre-treated patients.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/49",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-49",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 50,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes survival curves, bioluminescence imaging of mice, and tumor frequency metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/50",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-50",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 51,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a standard biological signaling pathway map to demonstrate the mechanism of action of the drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/51",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-51",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 52,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes logos for BeiGene and Novartis.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/52",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-52",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 53,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a comparison of iMX-111 size vs IgG antibody, GLUT1 expression across tissues, correlation with cancer stage, and a survival curve.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/53",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-53",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 54,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a combination of mechanism diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/54",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-54",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
      "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-03-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 55,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a bar chart comparison to establish a benchmark for clinical efficacy in the IBD market.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/55",
      "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
      "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-55",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}